PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study

OBJECTIVE: Arterial thrombosis leading to ischemic injury worsens the prognosis of many patients with cardiovascular disease. PZ-128 is a first-in-class pepducin that reversibly inhibits PAR1 (protease-activated receptor 1) on platelets and other vascular cells by targeting the intracellular surface...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Arterioscler Thromb Vasc Biol
Autori principali: Kuliopulos, Athan, Gurbel, Paul A., Rade, Jeffrey J., Kimmelstiel, Carey D., Turner, Susan E., Bliden, Kevin P., Fletcher, Elizabeth K., Cox, Daniel H., Covic, Lidija
Natura: Artigo
Lingua:Inglês
Pubblicazione: Lippincott Williams & Wilkins 2020
Soggetti:
Clinical and Population Studies
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7682800/
https://ncbi.nlm.nih.gov/pubmed/33028101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.120.315168
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi